High Pressure Non Invasive Ventilation in Hypercapnic Respiratory Failure
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04362787|
Recruitment Status : Not yet recruiting
First Posted : April 27, 2020
Last Update Posted : July 13, 2020
|Condition or disease||Intervention/treatment|
|Acute Hypercapnic Respiratory Failure||Device: High pressure non invasive ventilation in acute hypercapnic respiratory failure|
Noninvasive ventilation (NIV): refers to the administration of ventilatory support without using an invasive artificial airway (endotracheal tube or tracheostomy tube). NPPV is well established in the management of acute on chronic hypercapnic respiratory failure secondary to acute exacerbation of COPD (AECOPD), obesity hypoventilation syndrome, and restrictive thoracic disorders.
During the past years NIV was applied by using low pressure inspiratory positive airway pressure (IPAP), which means titrating inspiratory pressure starting at 10 cmH2O and increasing pressure gradually according to patient tolerance maximum up to 20 cm H2O.
There is still about 15% failure rate while using conventional low pressure NIV, this failure rate may be attributed to the following:
- Still in a number of patients with conventional low pressure NIV, PaCO2, and pH worsen with subsequent deterioration and need for invasive ventilation.
- Despite lowering PaCO2 value with conventional NIV ventilation but it is not normalized so with minimal derangement in clinical condition of the patient it worsens again.
- Also abnormally high level PaCO2 may have a negative impact on vital organs.
- Low pressure may be associated with patient intolerance , and discontinuation of NIV.
Recently high pressure NIV used aiming to improve outcome of NIV. High pressure NIV is a pressure limited ventilation, stating IPAP pressure at 20 cmH2O and gradually increasing pressure up to 30 cmH2O according to patient tolerance. High pressure NIV is expected to improve alveolar ventilation, decreasing dead space ventilation, and work of breathing, so it can improve the outcome result .
|Study Type :||Observational|
|Estimated Enrollment :||52 participants|
|Official Title:||High Pressure Non Invasive Ventilation in Hypercapnic Respiratory Failure|
|Estimated Study Start Date :||August 1, 2020|
|Estimated Primary Completion Date :||April 1, 2022|
|Estimated Study Completion Date :||April 1, 2023|
High pressure _ low pressure non-invasive ventilation
In the high-pressure NIV,52 patients will undergo pressure-limited NPPV at a higher IPAP level. IPAP is initially set at 20 cmH2O and continuously adjusted by increments and decrements of 1-2 cmH2O (up to 30 cmH2O), according to patients' tolerance, to obtain a tidal volume (VT) of 15 mL/kg of IBW.
2- EPAP for patients with COPD will be started at EPAP 5 and will be increased till 7 and for the patients with hypoventilation syndrome will be increased up to EPAP 8.
3-Respiratory rate 10-12 b/min.
Device: High pressure non invasive ventilation in acute hypercapnic respiratory failure
Usage of High pressure non invasive ventilation in acute hypercapnic respiratory failure
- High pressure non invasive ventilation in acute hypercapnic respiratory failure [ Time Frame: Patients will assessed after 2 hours from increasing pressure ]To study the efficacy of safety of high pressure NIV in acute hypercapnic respiratory failure due to COPD and obesity hypoventilation syndrome who refractory to low pressure NIV.
- High pressure non invasive ventilation in acute hypercapnic respiratory failure [ Time Frame: Patients will assessed after 2 hours from increasing pressure ]Effect of high pressure NIV on length of hospital stay , need for invasive mechanical ventilation, mortality.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04362787
|Contact: Maha Ei Abdelhafeez, Master||010911477791 ext email@example.com|
|Study Director:||Khaled Hu Ahmed||Professor of chest diseases Faculty of medicine Assiut university|